Navigation Links
NeurogesX to Present at J.P. Morgan Health Care Conference
Date:1/16/2010

s leveraged its passion to help people with pain to efficiently develop this concept and is now poised to bring its lead product to patients and physicians. In addition, we continue to apply our knowledge and expertise in the development of other novel treatments for pain.

The Company's lead product, Qutenza® (capsaicin) 8% patch, is a dermal delivery system containing a prescription strength of capsaicin that is currently approved in the United States and the European Union. NeurogesX expects to launch Qutenza in United States in the first half of 2010 for patients with postherpetic neuralgia (PHN). In Europe, Qutenza will be marketed by Astellas Pharma Europe Ltd., (Astellas), the European subsidiary of Tokyo-based Astellas Pharma Inc.

The Company's second most advanced product candidate, NGX-1998, is a topically applied, liquid formulation containing a high concentration of capsaicin designed to treat pain associated with neuropathic pain conditions. NGX-1998 has completed three Phase 1 studies.

The Company's early stage product pipeline includes pre-clinical compounds which are prodrugs of acetaminophen and various opioids. The Company has evaluated these compounds in vitro and in vivo.

Safe Harbor Statement

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). NeurogesX disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include but are not limited to: statements about the safety and efficacy of Qutenza®; the timing of launch of Qutenza; and development activities for NGX-1998 and other product candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks an
'/>"/>

SOURCE NeurogesX, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. NeurogesX to Present at Piper Jaffray Health Care Conference
2. NeurogesX Reports Third Quarter 2009 Results
3. NeurogesX to Present at Two November Conferences
4. NeurogesX to Present at UBS Global Life Sciences Conference
5. NeurogesX to Present at Upcoming Fall Conferences
6. NeurogesX Appoints New Board Director and Audit Committee Chairman
7. NeurogesX Reports Second Quarter 2009 Results
8. NeurogesX Announces New PDUFA Date for Qutenza(TM) New Drug Application
9. NeurogesX to Hold Conference Call to Discuss Second Quarter 2009 Financial Results
10. NeurogesX Added to Russell 3000 Index
11. NeurogesX Provides U.S. Regulatory Update for Qutenza(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... 23, 2013 Virobay, Inc. today announced that ... reached an important milestone, as Virobay has now initiated ... selective cathepsin S inhibitor.   The first ... placebo-controlled study designed to evaluate the safety, tolerability, pharmacokinetics ... adults. "The initiation of this Phase 1 ...
(Date:5/23/2013)... Northwest Biotherapeutics (NASDAQ: NWBO ) ... personalized immune therapies for solid tumor cancers, announced today ... American Society Of Clinical Oncology (ASCO) meeting in ... in immune therapy.  (Logo: http://photos.prnewswire.com/prnh/20110329/SF73084LOGO ) ... pre-eminent conference focused on clinical treatment of cancer, with ...
(Date:5/23/2013)... 2013 During the conduct of ... adhere to principles of good clinical practice (GCP) ... Dr. Jeremy Lim, Fellow, Clinical Development at Novartis ... ,     Understand the International Conference on Harmonization (ICH) ... regulations for the conduction of clinical trials , ...
(Date:5/23/2013)... May 23, 2013 Bed bugs already cost ... pests is still ongoing, a report from kmov.com suggested that ... the bed bug treatment. Meanwhile, to be of help, My ... the costly bed bug exterminator service. , The ... AHA has so far spent $35,000 for bed ...
Breaking Biology Technology:Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 3NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 2NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 3Adhering to Good Clinical Practice, New Webinar Hosted by Xtalks 2Bed Bug Exterminator Service Could Cost AHA $250K, My Cleaning Products Gives Tips How to Save Apartments from Costly Bed Bug Treatment 2
... vein treatment methods led by Dr. Sinjae Hyun, associate professor of biomedical ... he will present this summer to his research collaborators and the company. ... ... California company aided in the research of vein treatment methods ...
... Therapeutics, Inc. (CTI),(Nasdaq and MTA: CTIC) announced today ... accepted for filing and review, and has granted,priority ... for use of Zevalin(R) ([90Y]-ibritumomab tiuxetan) as consolidation,therapy ... achieve,a response to first-line therapy. Priority review is ...
... ENCO ), a full service multinational clinical ... many of the world,s leading,pharmaceutical and biotechnology companies, today ... from Nasdaq stating that since it had not yet,filed ... 2008 as of the,date of the letter, it was ...
Cached Biology Technology:Gift Aids Professor's Research into Vein Treatment 2Gift Aids Professor's Research into Vein Treatment 3Gift Aids Professor's Research into Vein Treatment 4FDA Accepts Cell Therapeutics' Zevalin sBLA and Grants Priority Review 2FDA Accepts Cell Therapeutics' Zevalin sBLA and Grants Priority Review 3FDA Accepts Cell Therapeutics' Zevalin sBLA and Grants Priority Review 4FDA Accepts Cell Therapeutics' Zevalin sBLA and Grants Priority Review 5Encorium Announces Receipt of Letter from Nasdaq Regarding its Third Quarter 2008 Form 10-Q Filing 2Encorium Announces Receipt of Letter from Nasdaq Regarding its Third Quarter 2008 Form 10-Q Filing 3
(Date:5/22/2013)... 22, 2013)The omega 3 fatty acids in fish oil ... much so that the American Heart Association currently recommends ... particularly fatty varieties rich in omega 3s. However, the ... In a new study, scientists led by Jason R. ... phenomenon by providing evidence that fish oil might specifically ...
(Date:5/22/2013)... how climate change will affect interactions between species in ... of Animal Ecology . This knowledge, they say, is ... how species are likely to be impacted by rising ... among biologists that climate change is affecting how species ... to have very important consequences for the stability and ...
(Date:5/21/2013)... device attached to a whale entangled in fishing gear, ... changed a whale,s diving and swimming behavior. The monitoring ... and migrate, depletes their energy as they drag gear ... slow death. , The scientists in this entanglement response ... two-year-old female North Atlantic right whale called Eg 3911. ...
Breaking Biology News(10 mins):Fish oil may help the heart beat mental stress 2UCLA life scientists present new insights on climate change and species interactions 2UCLA life scientists present new insights on climate change and species interactions 3UCLA life scientists present new insights on climate change and species interactions 4UCLA life scientists present new insights on climate change and species interactions 5Study reveals how fishing gear can cause slow death of whales 2Study reveals how fishing gear can cause slow death of whales 3
... University of Akron researcher is leveraging advanced modeling ... organic materials bond to inorganic materials, a natural ... design of composite materials and devices for such ... generation and treatment of diseases. Hendrik Heinz, ...
... December, 2010 Elsevier, the world-leading publisher of scientific, ... that it is participating in the recently launched Google ... eBook titles. Elsevier regards Google eBooks as a valuable ... its scientific and professional ebook content in the United ...
... Diving blue whales can dive for anything up to ... Columbia, Canada, explains that blue whales may be able to ... could carry in their blood and muscles, so why don,t ... water must use a lot of energy, says Shadwick. Explaining ...
Cached Biology News:Simulations aim to unlock nature's process of biomineralization 2Elsevier offers scientific book content through Google eBooks 2Blue whale-sized mouthfuls make foraging super efficient 2
Mouse monoclonal antibody raised against a partial recombinant NEK2. NCBI Entrez Gene ID = NEK2...
... Minis 300V power supply (Cat. No. Minis ... sufficient for SDS-PAGE, and native PAGE applications. ... of terminator pairs can be used simultaneously. ... individuals to have his/her own power supply ...
... premium quality recombinant form of Thermus aquaticus ... for a wide range of PCR applications. ... performance, each preparation is extensively tested in ... DNA Polymerase possesses an integral 5′→3′ exonuclease ...
Mouse monoclonal antibody raised against a partial recombinant COG2. NCBI Entrez Gene ID = COG2...
Biology Products: